286 related articles for article (PubMed ID: 30612711)
1. Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma.
Ansell SM
Lancet Haematol; 2019 Jan; 6(1):e2-e3. PubMed ID: 30612711
[No Abstract] [Full Text] [Related]
2. Pembrolizumab for classical Hodgkin's lymphoma.
Burki TK
Lancet Oncol; 2016 Aug; 17(8):e324. PubMed ID: 27397043
[No Abstract] [Full Text] [Related]
3. Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma.
Hradska K; Kascak M; Hajek R; Jelinek T
Expert Rev Hematol; 2020 Apr; 13(4):375-392. PubMed ID: 32116068
[No Abstract] [Full Text] [Related]
4. [Not Available].
Gilardin L; Amorim S; Bernard S; Ravdan O; Thieblemont C; Brice P
Bull Cancer; 2018 Dec; 105 Suppl 1():S50-S58. PubMed ID: 30595199
[TBL] [Abstract][Full Text] [Related]
5. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
[TBL] [Abstract][Full Text] [Related]
6. Brentuximab induced CD30
Nikolaou V; Iliakis T; Marinos L; Economidi A; Panayiotidis P; Rigopoulos D; Stratigos AJ
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):e147-e148. PubMed ID: 30520137
[No Abstract] [Full Text] [Related]
7. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
[No Abstract] [Full Text] [Related]
8. [Checkpoint inhibitors in Hodgkin lymphoma].
Sasse S; Momotow J; Engert A
Internist (Berl); 2020 Jul; 61(7):660-668. PubMed ID: 32462248
[TBL] [Abstract][Full Text] [Related]
9. Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma.
Manson G; Herbaux C; Brice P; Bouabdallah K; Stamatoullas A; Schiano JM; Ghesquieres H; Dercle L; Houot R;
Blood; 2018 Jun; 131(25):2856-2859. PubMed ID: 29724901
[No Abstract] [Full Text] [Related]
10. Checkpoint blockade after kidney transplantation.
Lesouhaitier M; Dudreuilh C; Tamain M; Kanaan N; Bailly E; Legoupil D; Deltombe C; Perrin P; Manson G; Vigneau C; Houot R
Eur J Cancer; 2018 Jun; 96():111-114. PubMed ID: 29705511
[No Abstract] [Full Text] [Related]
11. Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review.
Dada R
Ann Hematol; 2018 Apr; 97(4):555-561. PubMed ID: 29322203
[TBL] [Abstract][Full Text] [Related]
12. Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy.
Zahavi DJ; Weiner LM
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621125
[TBL] [Abstract][Full Text] [Related]
13. Back to life with checkpoint inhibitors in Hodgkin lymphoma.
Dada R; Zekri J
J Oncol Pharm Pract; 2018 Mar; 24(2):139-142. PubMed ID: 28597713
[TBL] [Abstract][Full Text] [Related]
14. Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre.
Rogers KA; Huang Y; Dotson E; Lundberg J; Andritsos LA; Awan FT; Woyach JA; Byrd JC
Br J Haematol; 2019 Apr; 185(2):363-366. PubMed ID: 30028000
[No Abstract] [Full Text] [Related]
15. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
Nie J; Wang C; Liu Y; Yang Q; Mei Q; Dong L; Li X; Liu J; Ku W; Zhang Y; Chen M; An X; Shi L; Brock MV; Bai J; Han W
J Clin Oncol; 2019 Jun; 37(17):1479-1489. PubMed ID: 31039052
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint Inhibition in Hodgkin Lymphoma - a Review.
Bröckelmann PJ; Engert A
Oncol Res Treat; 2017; 40(11):654-660. PubMed ID: 29065424
[TBL] [Abstract][Full Text] [Related]
17. Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma.
Qin Q; Nan X; Miller T; Fisher R; Teh B; Pandita S; Farach AM; Pingali SR; Pandita RK; Butler EB; Pandita TK; Iyer SP
Radiat Res; 2018 Sep; 190(3):322-329. PubMed ID: 29949442
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
Sagiv O; Thakar SD; Kandl TJ; Ford J; Sniegowski MC; Hwu WJ; Esmaeli B
JAMA Ophthalmol; 2018 Nov; 136(11):1236-1241. PubMed ID: 30352118
[TBL] [Abstract][Full Text] [Related]
19. Targeting Immune System Alterations in Hodgkin Lymphoma.
Grover NS; Savoldo B
Curr Hematol Malig Rep; 2017 Aug; 12(4):358-369. PubMed ID: 28780614
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab.
Villasboas JC; Ansell SM
Expert Rev Anticancer Ther; 2016; 16(1):5-12. PubMed ID: 26577822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]